Charles River Laboratories International (NYSE:CRL) EVP Shannon Parisotto Sells 2,156 Shares of Stock

Key Points

• Executive sale: EVP Shannon Parisotto sold 2,156 CRL shares for approximately $742,548 under a pre-arranged Rule 10b5-1 trading plan, reducing her direct ownership by 30.96% to 4,807 shares.
• Stock performance and earnings: CRL shares rose 1.6% to $345.08, near their 52-week high. The company reported quarterly EPS of $3.02, exceeding estimates of $2.77, while revenue reached approximately $1 billion but declined 2.7% year over year.
• Investor outlook: Institutional investors and hedge funds own 98.91% of the stock, while analysts maintain a consensus “Moderate Buy” rating with a $302.33 price target; the company’s FY 2026 EPS guidance is $11.15–$11.45.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 2,156 shares of the firm's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares of the company's stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.6%

Charles River Laboratories International stock traded up $5.42 during midday trading on Friday, hitting $345.08. 822,279 shares of the stock were exchanged, compared to its average volume of 947,095. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $351.21. The firm has a market cap of $16.47 billion, a P/E ratio of -71.15, a P/E/G ratio of 3.22 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company has a 50 day moving average price of $293.05 and a two-hundred day moving average price of $232.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of CRL. Signaturefd LLC raised its stake in Charles River Laboratories International by 563.5% during the third quarter. Signaturefd LLC now owns 8,865 shares of the medical research company's stock valued at $2,615,000 after buying an additional 7,529 shares in the last quarter. Evergreen Capital Management LLC bought a new position in Charles River Laboratories International during the 3rd quarter worth approximately $2,621,000. Sterling Capital Management LLC grew its position in shares of Charles River Laboratories International by 350.3% in the 3rd quarter. Sterling Capital Management LLC now owns 6,642 shares of the medical research company's stock worth $1,959,000 after acquiring an additional 5,167 shares in the last quarter. Yousif Capital Management LLC grew its position in shares of Charles River Laboratories International by 721.8% in the 3rd quarter. Yousif Capital Management LLC now owns 43,367 shares of the medical research company's stock worth $12,794,000 after acquiring an additional 38,090 shares in the last quarter. Finally, Compass Wealth Management LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $69,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CRL shares. Zacks Research raised Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a report on Friday, October 2nd. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Evercore set a $330.00 target price on Charles River Laboratories International in a research report on Friday, September 25th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $302.33.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.